Study of SGN-40 in Patients With Relapsed Diffuse Large B-Cell Lymphoma

• Status: Completed
• Trial end date: 2009-01-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a Phase II, open-label, multidose trial of SGN-40 designed to estimate objective response rate and assess toxicity in patients with relapsed DLBCL.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Seagen Inc.; Seattle Genetics, Inc.
• Collaborator: Genentech, Inc.
• Treatments: Dacetuzumab

Criteria

Inclusion Criteria:

• Diagnosis of DLBCL.

• Received at least one combination chemotherapy regimen with rituximab, such as R-CHOP, R-ESHAP or equivalent.

• Progression or relapse since most recent therapy.

• At least one measurable lesion that is both greater than or equal to 2 cm by conventional CT or greater than or equal to 1.5 cm by spiral CT.

Exclusion Criteria:

• Previous diagnosis or treatment for indolent lymphoma, leptomeningeal lymphoma, or central nervous system lymphoma.

• Primary refractory disease.

• Received an allogenic stem cell transplant.